A new generation of oral medications promises greater accessibility and potentially superior results in America's obesity battle. The pharmaceutical industry's race to develop pill-based alternatives to injectable weight-loss medications, including Ozempic and Wegovy, has reached a pivotal moment, with emerging formulations demonstrating results that surpass their needle-based predecessors. As Novo Nordisk introduces a once-daily oral…